- T2 Biosystems Inc (NASDAQ:TTOO) expects Q2 FY22 revenues of $5.8 million - $6.1 million, below the consensus of $6.87 million.
- The interim numbers include product revenue of $2.5 million - $2.7 million and research revenue of $3.3 million - $3.4 million.
- Executed contracts for 12 T2Dx Instruments during Q2, consisting of 6 in the U.S. and six outside the U.S.
- The company implemented expense reductions by eliminating 34 existing and 20 planned positions and decreasing operating expenses by approximately 20%.
- Also See: T2 Biosystems Secures Additional BARDA Funding To Develop Blood Test Panels To Detect Sepsis-Causing Pathogens.
- The company continues to expect FY22 revenue of $28.0 million - $31.0 million, compared to the consensus of $29.33 million.
- T2 Biosystems expects FY product revenue of $16.0 million - $17.0 million and research contribution revenue of $12.0 million - $14.0 million.
- It expects to close 60 - 70 T2Dx Instrument contracts in 2022 and COVID-19 revenue to decrease from $9.5 million to $3.5 million.
- Price Action: TTOO shares are down 19.47% at $0.15 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
T2 Biosystems Shares Slide As Interim Q2 Sales Trail Consensus
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks